Research programme: cereblon modulators - Monte Rosa Therapeutics
Alternative Names: Cereblon reprogramming - Monte Rosa TherapeuticsLatest Information Update: 28 Jun 2024
At a glance
- Originator Monte Rosa Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action CRBN protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 30 May 2020 Cereblon modulators - Monte Rosa Therapeutics is available for licensing as of 30 May. https://www.monterosatx.com/ (Monte Rosa Therapeutics website,
- 27 May 2020 Preclinical trials in Solid tumours in USA, prior May 2020 (unspecified route)